|Contact | About Us | My Acct | FAQ|
|Novartis AG is the designated Tech Seeker for this inknowvation@work® event. However, the emphasis on this occasion is primarily to addressing the technology needs and interests of Novartis OTC - itself, along with Animal Health, being part of Novartis Consumer Health.
|Senior Management||Daniel L Vasella|
|Extent and form of SBIR-STTR involvement|
|VC Entity||Yes||VC SBIR transactions|
|M/A transactions||4||ASSETs Involved|
|Working relationships||42||Points of contact|
A leader in the development, manufacture, sales, marketing and distribution world-wide of self-medication brands - those not requiring prescriptions - Novartis OTC has operations in every continent, standalone businesses in over 60 countries and distribution in over 120 countries. Capabilities include provision of coverage across multiple channels including pharmacies, drugstores, grocery & mass channel outlets, hospitals and doctors both specialists and general practitioners.
Main Therapeutic Areas:
relevant strategic brands
With Global presence, the firm has a robust portfolio of market leading brands covering most OTC segments. Products are designed for in-home treatment and for prevention of medical conditions and ailments. to include allergy symptoms, cough and cold, and respiratory condition; digestive health, pain management as well as analgesics, skin care products, smoking cessation treatments and mineral supplements. The main therapeutic categories addressed by Novartis OTC along with the associated, key strategic brands are
Through a concerted external outreach effort to include extensive reach-in to, and engagement of, the capacities and capabilities of the SBIR community, Novartis OTC is particularly focused to building on a strong record of Rx-to OTC switches and new product developments, These range from simple line extensions to achievement of industry firsts in new technologies and superior delivery systems.
Novartis AG has a long established history of working in successful partnerships with numerous technology and development companies around the world. Such partnerships have led to novel product offerings in the firms leading brands including the first launch of an edible thin film product for systemic drug delivery. Development experience also covers a wide range of dose forms including oral, orodispersible, topical, transdermal patches and gels/creams and nasal sprays.
Major SBIR-STTR presence already in place:
As indicated by the data in the accompanying Table (Top Right), Novartis AG has already established a strong presence with SBIR-STTR involved firms.